Novacyt obtient un financement de 4 millions d’euros par le biais d’une facilité d’emprunt non-garantie pour soutenir sa politique d’acquisition

Novacyt Financement Paris, France et Camberley, Royaume-Uni – le 30 mai 2018 – Novacyt (EURONEXT GROWTH : ALNOV; AIM : NCYT), spécialiste mondial du diagnostic clinique annonce avoir obtenu le 29 mai 2018 une nouvelle facilité d’emprunt non garantie de 4,0 millions d’euros auprès d’un investisseur institutionnel français (la « facilité d’emprunt»).

Visit Page

Novacyt secures €4.0m funding through unsecured debt facility to support M&A strategy

Novacyt Funding Paris, France and Camberley, UK – 30 May 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that on 29 May 2018, it entered into a new €4.0 million unsecured debt facility from a French institutional investor (the “Facility”).

Visit Page

Publication of Annual Report and Notice of AGM

Posting of AR and Notice of AGM FINAL Paris, France and Camberley, UK – 23 May 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2017 has today been published and uploaded to

Visit Page

RÉSULTATS ANNUELS 2017 DE NOVACYT

RÉSULTATS ANNUELS 2017 DE NOVACYT Croissance record de 35% du chiffre d’affaires Réduction significative des pertes opérationnelles Perspectives positives pour 2018  

Visit Page

NOVACYT FULL YEAR 2017 RESULTS

Novacyt FY17 financial results Record revenue growth of 35% Significantly narrowed losses Positive outlook for 2018

Visit Page

NOVACYT SIGNS ASSAY DEVELOPMENT CONTRACT FOR DIAGNOSIS OF RESPIRATORY INFECTIONS WITH GENEPOC

Further validation of Novacyt’s expertise in developing assays for clinical applications Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC Paris, France and Camberley, UK – 22 March 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign, has entered into

Visit Page

NOVACYT REVENUES FULL YEAR 2017

Novacyt revenues full year 2017 PR ENG Delivers record revenue growth of 35% China sales exceed expectations Successfully completed dual-listing on AIM

Visit Page

FOR THE THIRD YEAR RUNNING NOVACYT IS PLACED IN THE TECHNOLOGY FAST 500 EMEA AWARDS

Novacyt Fast 500 PR Paris, France and Cambridge, UK – 2 January 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte’s Technology Fast 500™ EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth in

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

Liquidity Agreement -1 December Paris, France and Cambridge, UK – 1 December 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by

Visit Page

FOR THE SECOND YEAR RUNNING NOVACYT WINS TECHNOLOGY FAST 50 AWARD

Novacyt Technology Fast 50 Award 2017 ENG Paris, France and Cambridge, UK – 7 November 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has won, for the second consecutive year, the Ile-de-France award of the Deloitte Technology Fast 50 French programme, an initiative that rewards fast

Visit Page